CAMP4 Therapeutics Corporation (NASDAQ:CAMP – Get Free Report) Director Andrew Schwab sold 32,018 shares of CAMP4 Therapeutics stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $4.50, for a total transaction of $144,081.00. Following the completion of the transaction, the director owned 2,433,280 shares of the company’s stock, valued at $10,949,760. The trade was a 1.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
CAMP4 Therapeutics Stock Up 0.4%
NASDAQ CAMP opened at $4.48 on Friday. The firm has a market cap of $281.12 million, a P/E ratio of -1.93 and a beta of 0.22. The company’s 50 day moving average is $4.12 and its 200-day moving average is $4.34. CAMP4 Therapeutics Corporation has a 12-month low of $1.41 and a 12-month high of $7.75.
CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%.The business had revenue of $1.78 million during the quarter. Equities analysts expect that CAMP4 Therapeutics Corporation will post -0.59 EPS for the current year.
Institutional Trading of CAMP4 Therapeutics
Analysts Set New Price Targets
A number of equities analysts have recently commented on CAMP shares. Chardan Capital set a $6.50 price target on CAMP4 Therapeutics and gave the stock a “buy” rating in a report on Wednesday, June 10th. Zacks Research upgraded CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 17th. JPMorgan Chase & Co. raised CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $5.00 to $9.00 in a report on Tuesday, June 16th. Weiss Ratings upgraded CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 14th. Finally, UBS Group set a $15.00 target price on CAMP4 Therapeutics in a report on Friday, August 14th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, CAMP4 Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $9.56.
Read Our Latest Report on CAMP4 Therapeutics
CAMP4 Therapeutics Company Profile
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.
Recommended Stories
- Five stocks we like better than CAMP4 Therapeutics
- Flash in the Pan or Sustained Rally Contender? 3 Momentum Stocks to Watch
- MarketBeat Week in Review – 08/17 – 08/21
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
Receive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
